180 related articles for article (PubMed ID: 31718159)
21. Co-delivery of DOX and PDTC by pH-sensitive nanoparticles to overcome multidrug resistance in breast cancer.
Cheng X; Li D; Sun M; He L; Zheng Y; Wang X; Tang R
Colloids Surf B Biointerfaces; 2019 Sep; 181():185-197. PubMed ID: 31132609
[TBL] [Abstract][Full Text] [Related]
22. Co-delivery of PDTC and doxorubicin by multifunctional micellar nanoparticles to achieve active targeted drug delivery and overcome multidrug resistance.
Fan L; Li F; Zhang H; Wang Y; Cheng C; Li X; Gu CH; Yang Q; Wu H; Zhang S
Biomaterials; 2010 Jul; 31(21):5634-42. PubMed ID: 20430433
[TBL] [Abstract][Full Text] [Related]
23. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin.
Jiang J; Yang SJ; Wang JC; Yang LJ; Xu ZZ; Yang T; Liu XY; Zhang Q
Eur J Pharm Biopharm; 2010 Oct; 76(2):170-8. PubMed ID: 20600887
[TBL] [Abstract][Full Text] [Related]
24. Reversal of multidrug resistance in vitro by co-delivery of MDR1 targeting siRNA and doxorubicin using a novel cationic poly(lactide-co-glycolide) nanoformulation.
Misra R; Das M; Sahoo BS; Sahoo SK
Int J Pharm; 2014 Nov; 475(1-2):372-84. PubMed ID: 25178825
[TBL] [Abstract][Full Text] [Related]
25. Tumor Targeting Synergistic Drug Delivery by Self-Assembled Hybrid Nanovesicles to Overcome Drug Resistance.
Gong MQ; Wu C; He XY; Zong JY; Wu JL; Zhuo RX; Cheng SX
Pharm Res; 2017 Jan; 34(1):148-160. PubMed ID: 27738951
[TBL] [Abstract][Full Text] [Related]
26. Reversal of P-glycoprotein-mediated multidrug resistance by CD44 antibody-targeted nanocomplexes for short hairpin RNA-encoding plasmid DNA delivery.
Gu J; Fang X; Hao J; Sha X
Biomaterials; 2015 Mar; 45():99-114. PubMed ID: 25662500
[TBL] [Abstract][Full Text] [Related]
27. Self-Assembling Doxorubicin Prodrug Forming Nanoparticles and Effectively Reversing Drug Resistance In Vitro and In Vivo.
Mao X; Si J; Huang Q; Sun X; Zhang Q; Shen Y; Tang J; Liu X; Sui M
Adv Healthc Mater; 2016 Oct; 5(19):2517-2527. PubMed ID: 27529558
[TBL] [Abstract][Full Text] [Related]
28. Sensitization of multidrug-resistant malignant cells by liposomes co-encapsulating doxorubicin and chloroquine through autophagic inhibition.
Gao M; Xu Y; Qiu L
J Liposome Res; 2017 Jun; 27(2):151-160. PubMed ID: 27250110
[TBL] [Abstract][Full Text] [Related]
29. Quick synthesis of a novel combinatorial delivery system of siRNA and doxorubicin for a synergistic anticancer effect.
Chen M; Wang L; Wang F; Li F; Xia W; Gu H; Chen Y
Int J Nanomedicine; 2019; 14():3557-3569. PubMed ID: 31190812
[No Abstract] [Full Text] [Related]
30. A smart tumor targeting peptide-drug conjugate, pHLIP-SS-DOX: synthesis and cellular uptake on MCF-7 and MCF-7/Adr cells.
Song Q; Chuan X; Chen B; He B; Zhang H; Dai W; Wang X; Zhang Q
Drug Deliv; 2016 Jun; 23(5):1734-46. PubMed ID: 25853477
[TBL] [Abstract][Full Text] [Related]
31. Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line.
Meng H; Liong M; Xia T; Li Z; Ji Z; Zink JI; Nel AE
ACS Nano; 2010 Aug; 4(8):4539-50. PubMed ID: 20731437
[TBL] [Abstract][Full Text] [Related]
32. Molecular mechanism study of chemosensitization of doxorubicin-resistant human myelogenous leukemia cells induced by a composite polymer micelle.
Han M; Diao YY; Jiang HL; Ying XY; Chen DW; Liang WQ; Gao JQ
Int J Pharm; 2011 Nov; 420(2):404-11. PubMed ID: 21945184
[TBL] [Abstract][Full Text] [Related]
33. Mesoporous silica nanoparticles loading doxorubicin reverse multidrug resistance: performance and mechanism.
Shen J; He Q; Gao Y; Shi J; Li Y
Nanoscale; 2011 Oct; 3(10):4314-22. PubMed ID: 21892492
[TBL] [Abstract][Full Text] [Related]
34. Reversal of P-glycoprotein-mediated multidrug resistance by doxorubicin and quinine co-loaded liposomes in tumor cells.
Shen Q; Qiu L
J Liposome Res; 2017 Dec; 27(4):293-301. PubMed ID: 27581212
[TBL] [Abstract][Full Text] [Related]
35. Codelivery of doxorubicin and JIP1 siRNA with novel EphA2-targeted PEGylated cationic nanoliposomes to overcome osteosarcoma multidrug resistance.
Haghiralsadat F; Amoabediny G; Naderinezhad S; Zandieh-Doulabi B; Forouzanfar T; Helder MN
Int J Nanomedicine; 2018; 13():3853-3866. PubMed ID: 30013340
[TBL] [Abstract][Full Text] [Related]
36. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer.
Wong HL; Bendayan R; Rauth AM; Wu XY
J Control Release; 2006 Dec; 116(3):275-84. PubMed ID: 17097178
[TBL] [Abstract][Full Text] [Related]
37. Mirror siRNAs loading for dual delivery of doxorubicin and autophagy regulation siRNA for multidrug reversing chemotherapy.
Yang B; Hao A; Chen L
Biomed Pharmacother; 2020 Oct; 130():110490. PubMed ID: 32712530
[TBL] [Abstract][Full Text] [Related]
38. A new polymer-lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells.
Wong HL; Rauth AM; Bendayan R; Manias JL; Ramaswamy M; Liu Z; Erhan SZ; Wu XY
Pharm Res; 2006 Jul; 23(7):1574-85. PubMed ID: 16786442
[TBL] [Abstract][Full Text] [Related]
39. Co-delivery of doxorubicin and P-gp inhibitor by a reduction-sensitive liposome to overcome multidrug resistance, enhance anti-tumor efficiency and reduce toxicity.
Tang J; Zhang L; Gao H; Liu Y; Zhang Q; Ran R; Zhang Z; He Q
Drug Deliv; 2016 May; 23(4):1130-43. PubMed ID: 25491241
[TBL] [Abstract][Full Text] [Related]
40. pH/Redox Dual-Responsive Polyplex with Effective Endosomal Escape for Codelivery of siRNA and Doxorubicin against Drug-Resistant Cancer Cells.
Gao Y; Jia L; Wang Q; Hu H; Zhao X; Chen D; Qiao M
ACS Appl Mater Interfaces; 2019 May; 11(18):16296-16310. PubMed ID: 30997984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
